Key Capital Corporation announced the Immunitor hepcortespenlisimut-L oral vaccine has demonstrated highly promising results in late-stage liver cancer patients. Groundbreaking Liver Cancer Immunotherapy: An open-label Phase II study of the hepcortespenlisimut-L immunotherapeutic vaccine conducted in 75 terminal stage patients with inoperable hepatocellular carcinoma (HCC) has shown that taking one Immunitor oral vaccine tablet per day is safe and highly effective as published in the open access Journal of Hepatocellular Carcinoma. The study demonstrated that after a median two months of treatment 50 out of 75 patients saw their hepatic tumor marker or alpha-fetoprotein (AFP) levels decline, indicating two-thirds of the study population responded to immunotherapy as the decrease in AFP levels was correlated with tumor shrinkage. Those patients who saw their AFP range fall to normal levels experienced tumor clearance, implying that they were in remission. In the study, there were 12 patients (16%) who had AFP levels below the 10 IU/ml threshold where the tumors were cleared. Further, over 90% of the patients were alive after median follow-up of 12 months as compared to a 10% overall survival rate in patients who received sorafenib, the first-line chemotherapy approved by the FDA in 2005. No adverse events or toxicity were observed at any time. Based on the encouraging data in HCC patients, hepcortespenlisimut-L has received orphan drug designation from the U.S. FDA (Food and Drug Administration) in 2014, clearing the path towards potential future approval in the US market. The Immunotherapy Research and Treatment Center in Guatemala will administer the Immunitor immunotherapy treatment and provide patient supervision and monitoring that is expected to lead to further patient data acquisition within a population where poverty and social conditions provide few alternative options.